🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#clinicaldata ~Masimo SedLine could improve #brain monitoring during #endoscopy, study says ~Spinex's #neuromodulation #tech ‘game-changing’ for children with #cerebralpalsy ~#RWE shows promise for C2N Diagnostics' PrecivityAD® #BloodTest

New real-world evidence released by ADDF-funded C2N Diagnostics shows that their PrecivityAD2 beta-amyloid #BloodTest helped correctly diagnose #Alzheimers in 87% of cases as compared to using standard assessment tools. Read more about the findings here: bit.ly/3YrEoiS

C₂N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, a Robust Assay with High Concordance to Amyloid PET and CSF #test #Alzheimer #dementia precivityad.com/news/cn-diagno…

.FierceBiotech reports on our release of the PrecivityAD2™ blood test for clinical care, a robust #assay w/ high concordance to amyloid PET & CSF fiercebiotech.com/medtech/c2n-di… #AlzheimersDisease

.Alzheimer's News Today reports on study published in ANA Journals that shows the PrecivityAD® blood test significantly influences clinicians’ decisions about whether to treat people with cognitive impairments for #Alzheimer’s disease. alzheimersnewstoday.com/news/precivity…

News from @medicaldevnet about the PrecivityAD2™ blood test that aims to set a new performance standard for blood biomarkers in #Alzheimer’s disease diagnosis w/ combined measures of amyloid beta (aβ42/40) & tau protein (p-tau217/np-tau217) ratios medicaldevice-network.com/news/c2n-diagn…

Happy #LaborDay Weekend

On #worldalzheimersday2023, C₂N Diagnostics’ PrecivityAD2™ blood test expands reach. The test availability through Grupo Fleury aims to help #Brazilians receive accurate, early #AlzheimersDisease #diagnosis c2n.com/news-releases/… #Brazil

advancements, expansion ~GenScript expands reagent services, adds #CircularRNA, #LipidNanoparticles formulation ~On #WorldAlzheimersDay, C2N Diagnostics expands #bloodtest reach ~Viz.ai expands #outpatient ambulatory centers to advance trial recruitment in #HeartFailure

Congratulations to Randall Bateman our CTAD Lifetime Achievement Award recipient in recognition for his pioneering work in Alzheimer's Disease Research and Plasma Biomarkers in AD diagnostics.

C2N Diagnostics introduces next-generation fluid biomarker to the field of #Alzheimer’s disease: Test to help researchers track neurofibrillary “tau” tangle pathology. #CTAD2023 c2n.com/news-releases/…

Congrats to our scientific co-founder Randall Bateman on receiving the CTAD Lifetime Achievement Award in recognition of his pioneering work in Alzheimer’s disease research and plasma biomarkers in AD diagnosis. #CTAD2023

C2N Sr. Medical Advisor Dr. Monane will present his research Gerontological Society of America (GSA) #GSA2023 in Tampa. "Patient Age And Sex Do Not Appear To Influence Decision Making Around Biomarker Testing for Cognitive Impairment.” Session 9550: 11/12, 10:00–11:30 a.m. room 413 #GSA2023 #Alzheimers

Researchers identify new cost savings and accuracy of C₂N Diagnostics’ blood tests to enable healthcare providers to better identify Alzheimer’s disease. #CTAD23 c2n.com/news-releases/…

Allston Brighton Community Fund is proud to support AllstonBrighton LL. For over 70 years, the Allston Brighton Little League has been part of our community. We can’t wait to hear “play ball!” #baseball #littleleague #AllstonBrighton leaguelineup.com/welcome.asp?ur…

Hats off to our supporters/sponsors/grantors: @MeilleurTechnologies, LantheusNews, Eli Lilly and Company, Alzheimer's Association, Eisai U.S. Neurology, Genentech, The Rainwater Charitable Foundation, Bristol Myers Squibb, Invicro, Life Molecular Imaging, Johnson & Johnson, C2N Diagnostics, Clario, AbbVie, Quanterix Big round of applause

C2N Diagnostics has entered into a non-exclusive agreement in select markets w/ Mayo Clinic Labs for inclusion of C2N’s Precivity™ tests in their test offerings. bit.ly/3XGmZo7#liquid… #precisionmedicine #Alzheimersdisease #MayoClinicLaboratories

Announcing a new DxA investment in C2N Diagnostics for over $7M—its largest investment to-date. This underscores the DxA’s commitment to developing & deploying #novel biomarkers—like #BloodTests—to transform the #Alzheimers diagnostic landscape: bit.ly/3TGx8yu

C2N announces partnership w/ michaeljfox.org to uncover new links b/w #ParkinsonsDisease #LewyBodyDementia & #AlzheimersDisease c2n.com/news-releases/…